Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748053 · ClinicalTrials.gov registry record · Phase 2
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
A Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
- 20
- Study locations
NCT06748053: Active Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
NCT06748053 is a Phase 2 study of Asthma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 307 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06748053, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK5784283
Study Locations (20)
Florida
- GSK Investigational Site - Aventura
- GSK Investigational Site - Hialeah
- GSK Investigational Site - Lake Worth
- GSK Investigational Site - Leesburg
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Plantation
California
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Redding
- GSK Investigational Site - Riverside
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Jose
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Lakewood
- GSK Investigational Site - Wheat Ridge
Arkansas
- GSK Investigational Site - Little Rock
Connecticut
- GSK Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2027-09-09 |
| Phase | Phase 2 |
What the registry record for NCT06748053 still lists
NCT06748053 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06748053 names 20 study sites across 5 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06748053 about?
NCT06748053 is a clinical study titled "A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma". This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma....
What is the current status of trial NCT06748053?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2025-02-10. Estimated completion is 2027-09-09.
What conditions does trial NCT06748053 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06748053?
The interventions under investigation include: Placebo (DRUG), GSK5784283 (DRUG).
Who is sponsoring clinical trial NCT06748053?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06748053 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06748053's enrollment target sits among peer trials
307 123rd of 374 higher than 252 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI